학술논문
Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).
Document Type
Journal
Author
Litton, Jennifer Keating; Laird, Douglas; Rugo, Hope S.; Ettl, Johannes; Hurvitz, Sara A.; Martin, Miguel; Roche, Henri; Im, Young-Hyuck; Goodwin, Annabel; Blum, Joanne Lorraine; Eiermann, Wolfgang; Chen, Ying; Lanzalone, Silvana; Chelliserry, Jijumon; Czibere, Akos; Albacker, Lee A.; Frampton, Garrett M.; Mina, Lida A.
Source
Subject
Language
English
ISSN
15277755